Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-HCC umbrella study in advanced hepatocellular carcinoma
CTR20210435Phase 2Active
- Sponsor
- Roche
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in hepatocellular carcinoma (HCC), sponsored by Roche. Started Sep 2021; status: active.
02
Drugs
tiragolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20210435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210435.